Copyright Reports & Markets. All rights reserved.

Global Chronic Idiopathic Constipation Drugs Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Chronic Idiopathic Constipation Drugs Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Chronic Idiopathic Constipation Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Linaclotide
    • 1.4.3 Lubiprostone
    • 1.4.4 Other
  • 1.5 Market by Application
    • 1.5.1 Global Chronic Idiopathic Constipation Drugs Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital Pharmacies
    • 1.5.3 Retail Pharmacies
    • 1.5.4 Online Pharmacies
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Chronic Idiopathic Constipation Drugs Market Perspective (2015-2026)
  • 2.2 Global Chronic Idiopathic Constipation Drugs Growth Trends by Regions
    • 2.2.1 Chronic Idiopathic Constipation Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Chronic Idiopathic Constipation Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Chronic Idiopathic Constipation Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Chronic Idiopathic Constipation Drugs Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Chronic Idiopathic Constipation Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Chronic Idiopathic Constipation Drugs Players by Market Size
    • 3.1.1 Global Top Chronic Idiopathic Constipation Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Chronic Idiopathic Constipation Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Chronic Idiopathic Constipation Drugs Market Concentration Ratio
    • 3.2.1 Global Chronic Idiopathic Constipation Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Chronic Idiopathic Constipation Drugs Revenue in 2019
  • 3.3 Chronic Idiopathic Constipation Drugs Key Players Head office and Area Served
  • 3.4 Key Players Chronic Idiopathic Constipation Drugs Product Solution and Service
  • 3.5 Date of Enter into Chronic Idiopathic Constipation Drugs Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Chronic Idiopathic Constipation Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Chronic Idiopathic Constipation Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)
  • 5.2 Global Chronic Idiopathic Constipation Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 6.2 Chronic Idiopathic Constipation Drugs Key Players in North America (2019-2020)
  • 6.3 North America Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 6.4 North America Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 7.2 Chronic Idiopathic Constipation Drugs Key Players in Europe (2019-2020)
  • 7.3 Europe Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 7.4 Europe Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

8 China

  • 8.1 China Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 8.2 Chronic Idiopathic Constipation Drugs Key Players in China (2019-2020)
  • 8.3 China Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 8.4 China Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 9.2 Chronic Idiopathic Constipation Drugs Key Players in Japan (2019-2020)
  • 9.3 Japan Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 9.4 Japan Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 10.2 Chronic Idiopathic Constipation Drugs Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

11 India

  • 11.1 India Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 11.2 Chronic Idiopathic Constipation Drugs Key Players in India (2019-2020)
  • 11.3 India Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 11.4 India Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Chronic Idiopathic Constipation Drugs Market Size (2015-2020)
  • 12.2 Chronic Idiopathic Constipation Drugs Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Chronic Idiopathic Constipation Drugs Market Size by Type (2015-2020)
  • 12.4 Central & South America Chronic Idiopathic Constipation Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Pfizer
    • 13.1.1 Pfizer Company Details
    • 13.1.2 Pfizer Business Overview
    • 13.1.3 Pfizer Chronic Idiopathic Constipation Drugs Introduction
    • 13.1.4 Pfizer Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020))
    • 13.1.5 Pfizer Recent Development
  • 13.2 Glaxosmithkline
    • 13.2.1 Glaxosmithkline Company Details
    • 13.2.2 Glaxosmithkline Business Overview
    • 13.2.3 Glaxosmithkline Chronic Idiopathic Constipation Drugs Introduction
    • 13.2.4 Glaxosmithkline Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.2.5 Glaxosmithkline Recent Development
  • 13.3 Roche Holding AG
    • 13.3.1 Roche Holding AG Company Details
    • 13.3.2 Roche Holding AG Business Overview
    • 13.3.3 Roche Holding AG Chronic Idiopathic Constipation Drugs Introduction
    • 13.3.4 Roche Holding AG Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.3.5 Roche Holding AG Recent Development
  • 13.4 Sanofi
    • 13.4.1 Sanofi Company Details
    • 13.4.2 Sanofi Business Overview
    • 13.4.3 Sanofi Chronic Idiopathic Constipation Drugs Introduction
    • 13.4.4 Sanofi Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.4.5 Sanofi Recent Development
  • 13.5 Bayer AG
    • 13.5.1 Bayer AG Company Details
    • 13.5.2 Bayer AG Business Overview
    • 13.5.3 Bayer AG Chronic Idiopathic Constipation Drugs Introduction
    • 13.5.4 Bayer AG Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.5.5 Bayer AG Recent Development
  • 13.6 Merck
    • 13.6.1 Merck Company Details
    • 13.6.2 Merck Business Overview
    • 13.6.3 Merck Chronic Idiopathic Constipation Drugs Introduction
    • 13.6.4 Merck Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.6.5 Merck Recent Development
  • 13.7 Eli Lilly
    • 13.7.1 Eli Lilly Company Details
    • 13.7.2 Eli Lilly Business Overview
    • 13.7.3 Eli Lilly Chronic Idiopathic Constipation Drugs Introduction
    • 13.7.4 Eli Lilly Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.7.5 Eli Lilly Recent Development
  • 13.8 Allergens
    • 13.8.1 Allergens Company Details
    • 13.8.2 Allergens Business Overview
    • 13.8.3 Allergens Chronic Idiopathic Constipation Drugs Introduction
    • 13.8.4 Allergens Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.8.5 Allergens Recent Development
  • 13.9 Chugai Pharmaceutical
    • 13.9.1 Chugai Pharmaceutical Company Details
    • 13.9.2 Chugai Pharmaceutical Business Overview
    • 13.9.3 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Introduction
    • 13.9.4 Chugai Pharmaceutical Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.9.5 Chugai Pharmaceutical Recent Development
  • 13.10 Ferring International Center S.A
    • 13.10.1 Ferring International Center S.A Company Details
    • 13.10.2 Ferring International Center S.A Business Overview
    • 13.10.3 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Introduction
    • 13.10.4 Ferring International Center S.A Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 13.10.5 Ferring International Center S.A Recent Development
  • 13.11 Synergy Pharmaceuticals
    • 10.11.1 Synergy Pharmaceuticals Company Details
    • 10.11.2 Synergy Pharmaceuticals Business Overview
    • 10.11.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Introduction
    • 10.11.4 Synergy Pharmaceuticals Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.11.5 Synergy Pharmaceuticals Recent Development
  • 13.12 Salix Pharmaceuticals Ltd
    • 10.12.1 Salix Pharmaceuticals Ltd Company Details
    • 10.12.2 Salix Pharmaceuticals Ltd Business Overview
    • 10.12.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Introduction
    • 10.12.4 Salix Pharmaceuticals Ltd Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.12.5 Salix Pharmaceuticals Ltd Recent Development
  • 13.13 Sucampo Pharmaceuticals Inc
    • 10.13.1 Sucampo Pharmaceuticals Inc Company Details
    • 10.13.2 Sucampo Pharmaceuticals Inc Business Overview
    • 10.13.3 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Introduction
    • 10.13.4 Sucampo Pharmaceuticals Inc Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.13.5 Sucampo Pharmaceuticals Inc Recent Development
  • 13.14 Ironwood Pharmaceuticals Inc
    • 10.14.1 Ironwood Pharmaceuticals Inc Company Details
    • 10.14.2 Ironwood Pharmaceuticals Inc Business Overview
    • 10.14.3 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Introduction
    • 10.14.4 Ironwood Pharmaceuticals Inc Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.14.5 Ironwood Pharmaceuticals Inc Recent Development
  • 13.15 Bausch Health
    • 10.15.1 Bausch Health Company Details
    • 10.15.2 Bausch Health Business Overview
    • 10.15.3 Bausch Health Chronic Idiopathic Constipation Drugs Introduction
    • 10.15.4 Bausch Health Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.15.5 Bausch Health Recent Development
  • 13.16 Daiichi Sankyo
    • 10.16.1 Daiichi Sankyo Company Details
    • 10.16.2 Daiichi Sankyo Business Overview
    • 10.16.3 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Introduction
    • 10.16.4 Daiichi Sankyo Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.16.5 Daiichi Sankyo Recent Development
  • 13.17 Cosmo Pharmaceuticals SA
    • 10.17.1 Cosmo Pharmaceuticals SA Company Details
    • 10.17.2 Cosmo Pharmaceuticals SA Business Overview
    • 10.17.3 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Introduction
    • 10.17.4 Cosmo Pharmaceuticals SA Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.17.5 Cosmo Pharmaceuticals SA Recent Development
  • 13.18 Progenics Pharmaceuticals Inc
    • 10.18.1 Progenics Pharmaceuticals Inc Company Details
    • 10.18.2 Progenics Pharmaceuticals Inc Business Overview
    • 10.18.3 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Introduction
    • 10.18.4 Progenics Pharmaceuticals Inc Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.18.5 Progenics Pharmaceuticals Inc Recent Development
  • 13.19 Theravance Biopharma Inc
    • 10.19.1 Theravance Biopharma Inc Company Details
    • 10.19.2 Theravance Biopharma Inc Business Overview
    • 10.19.3 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Introduction
    • 10.19.4 Theravance Biopharma Inc Revenue in Chronic Idiopathic Constipation Drugs Business (2015-2020)
    • 10.19.5 Theravance Biopharma Inc Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Chronic Idiopathic Constipation Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Idiopathic Constipation Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Pfizer
    Glaxosmithkline
    Roche Holding AG
    Sanofi
    Bayer AG
    Merck
    Eli Lilly
    Allergens
    Chugai Pharmaceutical
    Ferring International Center S.A
    Synergy Pharmaceuticals
    Salix Pharmaceuticals Ltd
    Sucampo Pharmaceuticals Inc
    Ironwood Pharmaceuticals Inc
    Bausch Health
    Daiichi Sankyo
    Cosmo Pharmaceuticals SA
    Progenics Pharmaceuticals Inc
    Theravance Biopharma Inc

    Market segment by Type, the product can be split into
    Linaclotide
    Lubiprostone
    Other
    Market segment by Application, split into
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now